Hypersensitivity reactions from taxol.

Weiss, Raymond B.; Donehower, Ross C.; Wiernik, Peter H.; Ohnuma, Takao; Gralla, R.; Trump, Donald L.; Baker, James R.; Echo, David A. Van; Hoff, Daniel D. Von; Leyland-Jones, B

doi:10.1200/jco.1990.8.7.1263

Cited by 1,086 publications

(673 citation statements)

References 16 publications

Supporting

Mentioning

642

Contrasting

Unclassified

Order By: Relevance

“…Hypersensitivity reactions to platinum compounds are a wellknown phenomena (Weiss, 1992). In the 1950s, literature reported the capacity of platinum salts to induce bronchial asthma among platinum-refinery workers (Hunter et al, 1945).…”

Section: Discussionmentioning

confidence: 99%

Hypersensitivity reactions related to oxaliplatin (OHP)

et al. 2003

View full text Add to dashboard Cite

Patients treated with platinum compounds are subject to hypersensitivity reactions. Our study has highlighted the reactions related to oxaliplatin (OHP) infusion. One hundred and twenty-four patients affected by advanced colorectal cancer were treated with different schedules containing OHP, at the Institute of Haematology and Medical Oncology 'L. and A. Seragnoli' of Bologna and at the Medical Oncology Division of Livorno Hospital. Seventeen patients (13%) showed hypersensitivity reactions after a few minutes from the start of the OHP infusion. Usually, these reactions were seen after 2 -17 exposures to OHP (Mean7s.e.: 9.471.07). No patient experienced allergic reactions at his/her first OHP infusion. Eight patients developed a mild reaction consisting of flushing and swelling of the face and hands, itching, sweating and lachrymation. The remaining nine patients showed a moderatesevere reaction with dyspnoea, wheezing, laryngospasm, psycho-motor agitation, tachycardia, precordial pain, diffuse erythema, itching and sweating. Six patients out of 17 were re-exposed to the drug with premedication of steroids and all except one developed the hypersensitivity reaction again. The cumulative dose, the time of exposure to OHP and the clinical features are variable and unpredictable. The risk of developing hypersensitivity reactions in patients treated with a short infusion of OHP cannot be underestimated.

show abstract

Section: Discussionmentioning

confidence: 99%

Hypersensitivity reactions related to oxaliplatin (OHP)

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Paclitaxel (taxol) (TAX), an anticancer agent, whose therapeutic efficacy is limited by its poor aqueous solubility [43] is currently administered in a mixture of Cremophor EL (polyoxyethylated castor oil) and dehydrated ethanol [44] to increase bioavailability. Systemic administration of taxol is associated with several negative side effects in patients including dyspnea, hypotension, broncho-spasm, urticaria, and erythematous rashes [44].…”

Section: Therapeutic Applications Of Polymersomesmentioning

confidence: 99%

“…Systemic administration of taxol is associated with several negative side effects in patients including dyspnea, hypotension, broncho-spasm, urticaria, and erythematous rashes [44]. In addition, the formulation agent (Cremophor EL) used to solubilize the hydrophobic taxol is believed to be responsible for inducing the hypersensitivity reactions observed in patients [44]. As a result, various aqueous formulations of taxol have been examined to decrease toxic side effects and increase water solubility.…”

Section: Therapeutic Applications Of Polymersomesmentioning

confidence: 99%

Polymersomes: A new multi-functional tool for cancer diagnosis and therapy

Levine

Ghoroghchian

Freudenberg

et al. 2008

Methods

199

122

View full text Add to dashboard Cite

Nanoparticles are being developed as delivery vehicles for therapeutic pharmaceuticals and contrast imaging agents. Polymersomes (mesoscopic polymer vesicles) possess a number of attractive biomaterial properties that make them ideal for these applications. Synthetic control over block copolymer chemistry enables tunable design of polymersome material properties. The polymersome architecture, with its large hydrophilic reservoir and its thick hydrophobic lamellar membrane, provides significant storage capacity for both water soluble and insoluble substances (such as drugs and imaging probes). Further, the brush-like architecture of the polymersome outer shell can potentially increase biocompatibility and blood circulation times. A further recent advance is the development of multi-functional polymersomes that carry pharmaceuticals and imaging agents simultaneously. The ability to conjugate biologically active ligands to the brush surface provides a further means for targeted therapy and imaging. Hence, polymersomes hold enormous potential as nanostructured biomaterials for future in vivo drug delivery and diagnostic imaging applications.

show abstract

“…Additionally, PTX's very low water solubility is a real problem in intravenous administration; PTX is currently administered in a vehicle containing Cremophor EL ® (polyethoxylated castor oil) and ethanol. Significant side effects associated with hypersensitivity to Cremophor EL ® have been observed (Dorr, 1994;Fjallskog et al, 1993), and premedication with corticosteroids and antihistamines is often required (Weiss et al, 1990). In order 60 to overcome these problems, new aqueous-based formulations for PTX, that do not require solubilization by Cremophor EL ® , have been developed (Marupudi et al, 2007;Skwarczynski et al, 2006).…”

mentioning

confidence: 99%

Preparation and characterization of novel poly(ethylene glycol) paclitaxel derivatives

Berlier¹,

Stella²,

Schiavon³

et al. 2013

International Journal of Pharmaceutics

View full text Add to dashboard Cite

25Paclitaxel has been found to be very effective against several human cancers; one of the major problems with its use is its poor solubility, which makes necessary its solubilization with excipients that can determine allergic reactions often severe. The aim of this study is to develop highly watersoluble and less toxic analogues of paclitaxel. For this purpose we prepared a series of new paclitaxel-poly(ethylene glycol) (PEG) conjugates that were characterized and evaluated for their in 30 vitro stability and cytotoxicity. In particular, in order to modulate the release of paclitaxel from prodrugs, we prepared different compounds introducing PEG in the drug C2' and/or C7 positions via ester or carbamate linkage. The conjugates were obtained in high purity and good yield. The carbamate prodrugs were highly stable in different media, while the compounds obtained linking PEG at C2' position through an ester bond showed lower stability. Finally, the cytotoxic activity of 35 the conjugates was evaluated on two cancer cell lines and the results showed that all the derivatives had a reduced cytotoxicity compared to that of paclitaxel.

show abstract

Hypersensitivity reactions from taxol.

Cited by 1,086 publications

References 16 publications

Hypersensitivity reactions related to oxaliplatin (OHP)

Hypersensitivity reactions related to oxaliplatin (OHP)

Polymersomes: A new multi-functional tool for cancer diagnosis and therapy

Preparation and characterization of novel poly(ethylene glycol) paclitaxel derivatives

Contact Info

Product

Resources

About